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Summary Interferon alpha (IFN-a) has a documented activity against malignant melanoma with a response
rate of only approximately 20%. It would therefore be of considerable importance if patients likely to respond
could be identified. The degree of mononuclear cell infiltration in primary tumours has been reported to
correlate with a favourable prognosis. This investigation used monoclonal antibodies, anti-CD4, -CD8 and -
CD1 lc, to identify subsets of tumour-infiltrating mononuclear cells in fine needle aspirates to study whether the
presence of such cells correlates with the therapeutic effect of IFN-a. Twenty-one patients with systemic and 20
with regional metastatic malignant melanoma were studied before initiation of IFN-a treatment. A statistically
significant correlation (P<0.001) was found between the occurrence of CD4+ lymphocytes in fine needle
aspirates and the therapeutic benefit of IFN-a in patients with systemic disease. Ten out of 11 with moderate to
high numbers of infiltrating CD4+ lymphocytes achieved tumour regression. In contrast, among patients with
low numbers of these cells in metastatic lesions, nine out of ten had progressive disease. Similar results were
found in patients with regional disease.
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Immune reactivity to malignant melanoma has been
suggested by spontaneous regressions (Hurwitz, 1991), the
occurrence of antibodies of prognostic significance against
melanoma-associated antigens (Jones et al., 1981) and specific
cytotoxic lymphocytes (Abershold et al., 1991). Conflicting
results have, however, been reported on the prognostic
significance of lymphocyte infiltration in primary malignant
melanoma. Some studies found a significantly better
prognosis if the primary lesions had a prominent infiltration
of lymphocytes (Hansen and McCarten, 1974; Lasen and
Grude, 1978), whereas others found no such correlation
(Balch et al., 1978). Three studies also found a relation
between tumour thickness and lymphocyte infiltration (Balch
et al., 1978; Hansen and McCarten, 1974; Larsen and Grude,
1978). Tumour-infiltrating lymphocytes were further studied
by McGovern et al. (1981), who found the infiltration at the
base of the melanoma to be of prognostic significance in
contrast to infiltration at the margins. McGovern et al. (1981)
also found that the lymphocyte infiltration at the tumour
base was reduced as tumour thickness increased. A reason-
able strategy to treat malignant melanoma would therefore be
to enhance the anti-tumour immune reactivity by immuno-
modulating substances, such as interferons and interleukin 2.
Interferon alpha (IFN-a) has a documented activity
against metastatic malignant melanoma (Legha, 1989). Five
to ten million units m-2 IFN-a three times weekly, at the cost
of reasonable side-effects, seems to be an optimal dose range
(Legha, 1989). The treatment efficacy varies in different
studies (Creagan et al., 1988; Legha, 1989) and the overall
response rate (CR+PR) to IFN-cx alone is only about 20%
(Creagan et al., 1988; Legha, 1989). It would therefore be a
considerable improvement if patients with a high probability
of responding to this treatment could be identified using
prognostic tests.
Besides having an anti-proliferative activity, the anti-
tumour effect of IFN-oa can be caused by the modulation of
tumour cells, e.g. increased expression of cell surface proteins
such as MHC I and tumour-associated antigens, which are of
importance for the immunological control of tumours. In
addition, IFN-a modulates several immune functions
(Balkwill, 1982). There are still no firm data demonstrating
which of the above-mentioned activities of IFN-ax is the most
important for the anti-tumour activity or whether they all
contribute.
As IFN-a modulates the activity of various cells in the
immune system (Knop, 1990; Gresser, 1990) the therapeutic
effect might depend on the immune status of the patients
when IFN-a therapy is initiated.
The aim of the present investigation was to study whether
the presence of subsets of tumour-infiltrating mononuclear
cells identified by immunocytochemical staining of fine needle
aspirates of metastatic malignant melanoma correlates with
the response to IFN-a.
Materials and methods
Patient data
This report describes 41 patients with metastatic malignant
melanoma, 23 males and 18 females. Median age was 60
years (range 33-77 years) and Karnofsky performance status
was 70 or more. Recurrences were cytologically verified by
fine needle aspirates before start of treatment. Two groups of
patients were studied, those with resectable regional disease
and those with systemic disease. Twenty patients had
metastases to regional lymph nodes, which in general were
excised after 1 to 3 weeks of IFN-cx treatment. Twenty-one
patients had systemic disease with the following metastatic
sites: two cutaneous, five subcutaneous, 16 lymph nodes,
eight pulmonary, four bone and 16 visceral (nine liver, one
ovarian, one pancreatic, one vulvar, one adrenal gland and
three spleen metastases). The number of metastatic sites were
one in six patients, two in seven patients, three in four
patients, four in one patient and five or more in three
patients. Except for one patient who had had chemotherapy,
no patient had previously been treated except for surgical
removal of primary lesions or metastases. Patients with
symptoms of brain metastases were not included in this
study.
Pretreatment investigations and treatment evaluation
These included electrocardiograph, abdominal computed
tomography, chest radiograph, bone scintigraphy and blood
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Treatment schedule
In a pilot study including 14 patients (six with regional
disease and eight with systemic disease), IFN-ax was given
subcutaneously (s.c.) 3 days weekly at a dose of 10 million IU
in combination with cyclophosphamide at a dose of
300 mg m-2 administered as intravenous (i.v.) bolus every 3
weeks and seven of these patients were also treated with
50 mg of indomethacin three times daily. One patient was on
cimetidine medication. This study was followed by the main
study including 27 patients (14 with regional resectable
disease and 13 with systemic disease). These patients were
treated with IFN-x alone at the same dose and schedule as in
the pilot study. In patients with regional resectable disease
the treatment could only be given for 1 -3 weeks in order not
to delay surgery. In patients with distant metastases
treatment continued until tumour progression. One treat-
ment cycle included 3 weeks of treatment followed by 1 week
without treatment. Tumour response was evaluated in
patients with regional resectable disease after 1 -3 weeks
and in patients with systemic disease after one (clinically
measurable disease) and three treatment cycles.
Monoclonal antibodies
CD4 (Leu-3a, Becton-Dickinson) The antigen is present on
the helper/inducer T subset and in low density on monocytes
and in the cytoplasm of monocytes and macrophages.
CD8 (Leu-2a, Becton-Dickinson) The antigen is present on
cytotoxic/suppressor lymphocytes. The antigen is also
expressed on some Leu- ll+ (CD16) cytotoxic natural killer
(NK) cells, on a subpopulation of Leu-7+ (HNK-1) cells
(which do not have cytotoxic and NK activity), on some Leu-
8+ cells (which participate in suppression of B-cell function),
and on Leu-15+ (CDllb) cells, which are associated with
suppressor function.
CDJJc (M5, Becton Dickinson) The antigen is present on
monocytes and in low density on granulocytes and large
granular lymphocytes in peripheral blood. It is also expressed
on macrophages in normal lymphoid tissue, on Kuppfer cells
in liver and alveolar macrophages in lung tissue.
Fine needle aspiration of metastases
Usually seven to ten aspirates were taken from each tumour
with a 0.6 mm hypodermic needle. The aspirate was smeared
on a glass slide and was allowed to dry in air. At least two
smears were then stained for conventional cytomorphology
according to the May-Grunewald-Giemsa method. In cases
without obvious melanin pigment in tumour cells, the
diagnosis of melanoma was confirmed with immunostaining
for vimentin and protein S-100. Morphological signs of
degeneration or necrosis were registered. Aspirates were
obtained from lymph node metastases in patients with
regional disease and from five subcutaneous, two liver and
14 lymph node metastases in patients with systemic disease.
Immunological staining offine needle aspirates
The slides were air dried and then fixed for 5 min in acetone.
After drying, the slides were washed in phosphate-buffered
saline (PBS), pH 7.6, and incubated with monoclonal
antibodies against CD4, CD8 and CD1 ic (see above) for
30 min. Mouse IgG (Sigma, Stockholm, Sweden) was used as
a negative control. After washing in PBS, the sections were
incubated with rabbit anti-mouse immunoglobulin (Dako-
patts Z 259) and incubated for 30 min, washed in PBS and
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incubated with the PAP mouse monoclonal antibody
(Dakopatts, P 850) for 30 min. After washing in PBS, the
slides were incubated in 50 ml PBS containing 40 mg
diaminobenzidine, DAB (Sigma, Stockholm, Sweden) and
0.6 ml 3% hydrogen peroxide for 6 min and washed. The
slides were counterstained in Mayer's haematoxylin for
15 min, washed and mounted in Glycergel (Dakopatts,
Sweden). All incubations were performed in a moist chamber.
Evaluation of mononuclear cells
Because of the often heterogeneous distribution ofinfiltrating
inflammatory cells, counting ofcells per microscopic field was
not performed. Instead, the overall occurrence of each subset
of these cells, in relation to the number of tumour cells, was
scored as low, moderate and high. CD4+ or CD11c+ cells
scored as lymphocytes had small or medium-sized nuclei and
sparse cytoplasm with distinct cell borders. In contrast,
CD4+ or CDl1c+ macrophages displayed large nuclei and
abundant, generally faintly staining, cytoplasm. The propor-
tion of lymphocytic vs non-lymphocytic CD4+ or CD1lc+
cells was registered. CD8+ cells always appeared as small or
medium-sized lymphocytes.
Preparation of tumour biopsies and immunological staining of
tissue sections
Biopsies from resected tumours were immediately snap frozen
and stored at -70°C until further processed. Frozen tissue
sections, 6-7 gm thick, were fixed in acetone for 10 min and
then air dried. They were washed in Tris-buffered saline (TBS),
pH 7.6, for 5 min, incubated with primary antibodies CD4,
CD8 and CD1 lc (see above) for 30 min and then washed in
TBS for 5 min. Mouse IgG (Sigma) was used as a negative
control. The sections were then incubated with rabbit anti-
mouse immunoglobulin (Dakopatts, Z 259) fo 30 min, washed
in TBS and incubated with the APAAP mouse monoclonal
antibody (Dakopatts D 651) for 30 min. After washing in TBS
and incubating with the alkaline phosphatase substrate
[naphthol AS-MX phosphate 2 mg (Sigma N4875), dimethyl-
formamide 0.2 ml, 0.1 M Tris buffer, pH 8.2 9.8 ml, 1 M
levamisole 50 /tl (Sigma L-9756) and fast red TR salt 10 mg
(Sigma F 1500)] for 20 min, the sections were washed again in
TBS. They were then counterstained in Mayer's haematoxylin
for 15 min and mounted in Glycergel (Dakopatts, Sweden).
All incubations were performed in a moist chamber.
Criteria of response in patients with systemic disease
(according to WHO)
Complete response (CR) Complete response was defined as
disappearance of all known disease.
Partial response (PR) A PR was defined as decrease of at
least 50% in the sum of the products of the largest
perpendicular diameters of measurable lesions determined
by two observations not less than 4 weeks apart. It is not
necessary for all lesions to have regressed to qualify for
partial response, but no lesion should have progressed and no
new lesions should appear.
Minor regressions These did not fulfil the criteria for partial
regression either because the reduction in the tumour size was
25-50% or because the duration ofthe response was too short.
Mixed response This was defined as measurable shrinkage
of some lesion and simultaneous progressive disease in some
other metastasis, or the appearance of new lesions.
Stable disease (SD) SD was considered to be present when
a 25% decrease in total tumour size could not be established
and a 25% increase in the size of one or more measurable
lesions could not be demonstrated. In addition, there is no
appearance of new lesions.CD4+ lymphocytes and response to IFN-a
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Progressive disease (PD) PD was defined as a 25% or more
increase in the size of at least one measurable lesion or the
appearance of a new lesion. As the objective of this study was
to analyse a correlation between the occurrence of tumour-
infiltrating inflammatory cells and the anti-tumour effect of
IFN-a, significant tumour regression (more than 25%) in
patients with minor regressions and mixed responses, not
fulfilling the criteria for partial remission, were used in the
following analysis.
Evaluation of tumour regression in patients with regional
metastases and criteria of histopathological tumour regression
Patients with regional, resectable metastases were treated with
IFN-a for 1-3 weeks before surgery. This is too short to
allow an adequate determination of the treatment efficacy
based on tumour size. Instead the occurrence of tumour
regression was evaluated by histopathological examination of
tumour biopsies. Based on the description of regressive
changes in primary malignant melanoma in other studies
(McGovern, 1975; Kang et al., 1993; Sondergaard and Hou-
Jensen, 1985; Ronan et al., 1987), the following criteria of
tumour regression were used in this study: (1) low and
variable density of tumour cells, particularly variation in
density within the same tumour nodule; (2) disorganisation of
the architecture of the tumour with nests of remaining
tumour cells surrounded by stromal tissue; (3) fibrosis.
However, the inflammatory infiltrate was not used as a
criterion of histopathological tumour regression in this study.
The signs of regression vary from no signs to almost
complete destruction with only a few tumour cells present.
The degree of tumour regression was considered minor when
regressive changes were estimated to be less than 25% (minor
regression) and marked when such changes were estimated to
be more than 25% (marked regression) of the section area.
Statistical method
For the final analyses the two studies were combined as no
differences were found between them regarding response rates
or histopathological regression or tumour-infiltrating inflam-
matory cells. The difference in distribution of inflammatory
cells between patients with tumour response and progressive
disease and between patients with and without histopatholo-
gical tumour regression was analysed using the chi-square
test. The pilot and main studies of patients with systemic
disease were analysed using Fisher's exact test.
Results
Comparison ofsubsets of tumour-infiltrating mononuclear cells
(MNCs) in fine needle aspirates in melanoma patients with
regional and systemic metastases
The number of tumour-infiltrating mononuclear cells in fine
needle aspirates of melanoma metastases before initiation of
IFN-a treatment (Figure 1) showed considerable individual
variation (Table I). There was also a difference between
metastases from patients with regional or systemic disease.
High numbers of CD4+ lymphocytes were found in
metastases from 10 out of 20 patients with regional
metastases but only in four out of 21 metastases from
patients with systemic disease (P<0.05).
When CD4+ cells were found in high numbers, more than
50% showed morphological characteristics of lymphocytes.
In contrast, in tumours with low to moderate numbers of
these cells, CD4+ macrophages were more abundant than
CD4+ lymphocytes in four out of ten patients with regional
disease and in two out of 17 patients with systemic disease.
There was no difference in the ratio of CD4+ and CD8+
cells between metastases from patients with regional or
systemic disease. CD4+ cells predominated over CD8+ cells
in seven out of 19 metastases from patients with regional
disease and in six out of 20 patients with systemic disease.
CD8+ cells were more abundant than CD4+ cells in two out
of 19 and two out of 20 metastases from patients with
regional and systemic disease respectively.
Metastases from patients with regional or systemic disease
were infiltrated to the same extent by macrophages. High
numbers of CDllc+ macrophages were found in four out of
19 metastases from patients with regional and in four out of
20 tumours from patients with systemic disease.
Comparison of tumour-infiltrating CD4+ lymphocytes in fine
needle aspirates and biopsies
Even if IFN-a might influence the recruitment of CD4+ cells
to tumours, there was, in general, a close correlation between
the occurrence of these cells in fine needle aspirates and in
biopsies after IFN-a treatment in 15 out of 20 patients.
Lower numbers of CD4+ cells in tissue sections compared
with aspirates were found in only three metastases, which
might be explained by remnants of normal lymph node tissue.
Alternatively a down-regulation might have occurred during
IFN-a treatment. Biopsies from two patients showed an
increase of CD4+ cells compared with aspirates. The size of
Figure 1 Occurrence of tumour-infiltrating CD4+ lymphocytes
in a fine needle aspirate from a metastasis before initiation of
IFN-a treatment. Scale bar=20 tim.
Table I Tumour-infiltrating CD4+ and CD8+ lymphocytes and CD11c+ macrophages in fine needle aspirates
from patients with regional and systemic disease before initiation of IFN-ax treatment
No. ofpatients with tumour-infiltrating cells before
initiation ofIFN-atreatment
Proportion ofcells in CD4 CD8 CDIIc
fine needle aspirates Regional Systemic Regional Systemic Regional Systemic
Low 6 10 9 14 8 8
Moderate 4 7 7 4 7 8
High 10 4 3 2 4 4lymph node metastases seems to be of some guidance as to
the presence of remaining normal lymph node. Remnants of
normal lymph node were found in seven out of 13 lymph
node metastases less than 20 mm in diameter in contrast to
only two out of seven in larger lymph node metastases.
Correlation between treatment efficacy and occurrence of
tumour-infiltrating mononuclear cells in patients with systemic
disease
Reduction in tumour size after IFN-a treatment was
registered in 11 out of 21 patients with systemic disease.
One had a complete remission, four partial remission, three
had a reduction of measurable tumours between 25 and 50%,
three had a mixed response and ten patients had progressive
disease. In order to register any capacity to respond to IFN-cx
treatment, mixed responses and early often short-lived minor
regressions not fulfilling the formal criteria for partial
remission were included in the analysis. The average time
to progression in patients with tumour regression and
progressive disease was 4.1 (median 2, range 1-14) and 1.6
(median 1, range 1-3) months respectively. The correspond-
ing figures for overall survival were 14+ (median 12, range
5-34+) for responders and 6.8 (median 5.5, range 1-15)
months for non-responders.
Eight out of 21 patients treated in a pilot study received
in addition to IFN-oc also immunomodulating drugs (see
above). However, none of these drugs per se, at the doses
used, have any documented anti-tumour effect against
melanoma. The occurrence of inflammatory cells in fine
needle aspirates in relation to the therapeutic effect of IFN-oc
is shown in Table II. Obviously there is a close correlation
between anti-tumour effects and the presence of CD4+
lymphocytes. In the pilot study, five out of eight patients
had moderate to high numbers of tumour-infiltrating CD4+
lymphocytes and all five achieved tumour regression. In
contrast, the three patients with low numbers of these cells
had progressive disease (P=0.04). Similarly, in the main
study, six out of 13 patients had moderate to high numbers
of these cells infiltrating the metastases and five of these six
patients responded to IFN-oc treatment, but only one out of
seven with low numbers of CD4+ lymphocytes achieved
tumour regression (P=0.06). As no differences regarding
tumour regression or occurrence of infiltrating inflammatory
cells were found between the pilot study and the main study
the patients of these studies were combined in a chi-square
analysis (P<0.001, for the three sub-groups shown in Table
II). Thus, moderate to high numbers of CD4+ lymphocytes
Table II Pretreatment tumour-infiltrating CD4+ and CD8+
lymphocytes and CD1 c+ macrophages in fine needle aspirates
from patients with inoperable systemic metastatic disease according
to clinical effect of IFN-ax treatment
No. ofpatients with tumour-infiltrating cells according
to tumour response
CD4 CD8 CDJJc
Proportion Response Response Response
ofinfiltrating category category category
cells R PD R PD R PD
Pilot study
Low 0 3 3 3 1 1
Moderate 3 0 1 0 2 0
High 2 0 0 0 1 2
Main study
Low 1 6 3 5 3 3
Moderate 3 1 1 2 3 3
High 2 0 2 0 0 1
Total study
Low 1 9 6 8 4 4
Moderate 6 1 * 2 2 5 3
High 4 0 2 0 1 3
*P<0.001. R, tumour regression; PD, progressive disease.
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were found in aspirates from 10 out of 11 responding
patients compared with one out of ten non-responders.
There was no correlation between the occurrence of CD8+
or CD1lc+ cells and response to IFN-cx treatment.
Correlation between treatment efficacy and occurrence of
tumour-infiltrating mononuclear cells in patients with regional
metastases
In order not to delay surgery, patients with regional,
resectable metastases were treated with IFN-cx for only 1-3
weeks. This is too short to allow an adequate determination
of the treatment efficacy based on tumour size. Therefore,
histopathological criteria used for tumour regression in
primary melanoma were applied in the evaluation of these
patients. Nine patients had marked histopathological
regression (Figure 2a) of the resected metastases and 11
patients had only minor or no regressive changes (Figure 2b).
Tumour areas with ongoing regression were generally
permeated by CD4+ cells, CD8+ lymphocytes as well as
CD11c+ cells (Figure 3a-c, but the occurrence of these cells
was not used as a criterion of regression in this study). The
average time to recurrence in patients with marked and minor
or no histopathological regression was 17.2 (median 12, range
2-74+) and 12.8 (median 9, range 1-14) months
respectively. The corresponding figures for overall survival
for these groups were 31 (median 20, range 12-74+) and 20
(median 19, range 11-45+) months.
The occurrence of inflammatory cells in relation to
histopathological regression is shown in Table III. Ob-
viously, there is a tendency to a correlation between anti-
tumour effect and the presence of tumour-infiltrating CD4+
lymphocytes also in patients with regional metastases. In the
Figure 2 (a) Marked tumour regression, with few scattered
tumour cells, in a tumour biopsy after IFN-a treatment, Scale
bar=20,pm. (b) No tumour regression in a tumour biopsy after
IFN-a treatment. There is a high density of tumour cells with
only few inflammatory cells. Scale bar=20ipm.CD4+ lymphocytes and response to IFN-a
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pilot study three out of five patients and in the main study
five out of nine patients with moderate to high numbers of
CD4+ lymphocytes achieved marked histopathological
regression. In contrast, five out of five patients in the main
study with low numbers of CD4+ lymphocytes had no or
only minor regressive changes in the metastases. When the
pilot and the main studies were analysed together, seven out
of ten patients with high numbers of tumour-infiltrating
CD4+ lymphocytes showed marked histopathological regres-
sion in contrast to only one out of six patients with low
numbers of these cells in the metastases (P=0.077, X2-test for
the three subgroups shown in Table III). There was no
correlation between the occurrence of CD8+ or CD 1 c+ cells
and response to IFN-a treatment.
Figure 3 (a) Occurrence of tumour-infiltrating CD4+ cells from
a tumour biopsy after IFN-oc treatment. Scale bar=20 gm. (b)
Occurrence of tumour-infiltrating CD8 + lymphocytes from a
tumour biopsy after IFN-a treatment. Scale bar =20 pm. (c)
Occurrence of tumour-infiltrating CDllc+ cells from a tumour
biopsy after IFN-a treatment. Scale bar=20ym.
Discussion
Mononuclear cells are involved in the immunological
destruction of tumour cells. However, these cells are likely to
carry several functions. Depending on immunogenicity and
stage oftumours, both anti-tumour and suppressor activity can
be expected. Asclinically manifest tumours have developed, the
regional immune defence, if it was ever rasied, must have
deteriorated. This is consistent with the findings that various
functions of tumour-infiltrating mononuclear cells were
suppressed (Hutchinson et al., 1981; Miescher et al., 1986;
Vose and Moore, 1985). The local immunosuppression was,
however, found to be reversible (Hutchinson et al., 1981). In
some tumours, particularly in primary malignant melanomas,
areas of tumour regression have been described (McGovern,
1975; Sondergaard and Hou-Jensen, 1985; Ronan et al., 1987;
Kang et al., 1993). This is in agreement with the presence of
specific cytotoxic lymphocytes as has been described in several
reports (Hutchinson et al., 1981; Rosenberg et al., 1986; Vose
and Moore, 1985).
Based on these considerations it seems reasonable in the
treatment of melanoma patients to try to overcome the
immunosuppression or to enhance the immune reactivity to
the tumours by immunomodulating substances. IFN-ax
modulates various functions of the immune system
(Balkwill, 1982). The therapeutic effect might therefore
depend on the presence of certain subsets of lymphocytes
or macrophages infiltrating the tumours.
As T lymphocytes and macrophages are considered to be
the most important cells for immunological control of
malignant tumours, the presence of these subsets of cells in
melanoma metastases has been analysed in the present study
on the effect of IFN-oa. This study demonstrated that the
presence of tumour-infiltrating CD4+ lymphocytes is of
importance for the therapeutic effect of IFN-a. It can thus
be concluded that one important anti-tumour effect of IFN-a
is to enhance the immune reactivity towards the tumour.
CD4+ lymphocytes predominated over CD8+ lymphocytes
and CD1 lc+ macrophages in most of our patients. The
occurrence of tumour-infiltrating inflammatory cells varies in
different studies. In a study by Tefany et al. (1991), the ratio
of CD4/CD8-positive cells infiltrating regressing tumours was
increased compared with non-regressing tumours. Others
found both CD4+ and CD8+ lymphocytes in melanoma
(Kornstein et al., 1983; Poppema et al., 1983). Ruiter et al.
(1982) found variation in the predominance of CD8+ and
CD4+ cells depending on tumour thickness. These conflicting
results might to some extent be explained by the complex
situation in these tumours, in which cytotoxic and
immunosuppressor activities can be expected to be present
simultaneously. The predominance ofCD4+ cells found by us
can be caused by either a preferential recruitment of these
cells or impaired proliferative response and reduced
clonogenic potential especially of tumour-infiltrating CD8+
cells (Miescher et al., 1988). The CD4+ predominance might
also be owing to stimulation by the cytokine RANTES which
has been shown to be an important chemotactic factor able
to stimulate migration and accumulation of CD4+ lympho-
cytes in solid tumours (Whiteside et al., 1992). As a positive
correlation with the therapeutic efficacy of IFN-a was found,
it is reasonable to assume that CD4+ lymphocytes are of
importance for the immune reactivity to the tumours. This is
in good agreement with tumour regression in seven out of 11
patients treated with in vitro activated tumour infiltrating
lymphocytes containing more than 80% CD4+ cells
(Rosenberg et al., 1988).
In order to evaluate properly a possible correlation
between response to treatment and a parameter of potential
predictive value, it is necessary to include all patients with
measurable tumour regression in the analysis, that is at least
also patients with minor regressions and mixed responses. It
could be argued that also patients with disease stabilisation
should be included in this group as the treatment actually
had an anti-tumour activity as tumour progression wasCDC phcisn dreipemibn
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Tabe m Pretreatment tumour-infiltrating CD4+ and CD8+ lymphocytes and CDllc macrophages in fine
needle aspirates from patients with regional disease according to degree ofhistopathological regression after IFN-a
treatment
No. ofpatients with tnuour-infltratig cells according to histopathological regression
CD4 CD8 CDIJc
Histopathological Histopathological Histopathological
Proportion ofcells in regression regression regression
fine needle aspirates Marked Minor Marked Minor Marked Minor
Pilot study
Low 1 0 2 1 1 2
Moderate 0 1 0 1 1 0
High 3 1 1 0 1 0
Main study
Low 0 5 1 5 2 3
Moderate 1 2 3 3 2 4
High 4 2 1 1 1 2
Total study
Low 1 5) 3 6 3 5
Moderate 1 3 3 4 3 4
High 7 3) 2 1 2 2
*P=0.077
stopped. However, these patients are more difficult to identify
accurately than those who achieve measurable regressions but
do not fulfil the formal criteria for partial remission. If only
patients with partial or complete remissions are regarded as
responders, other patients with measurable regression will be
erroneously allocated to the group of non-responders, which
will obscure the results. This misinterpretation of data may
be one reason why tests of predictive value for response to
immunotherapy have only rarely been found.
The reason why short-lived, minor regressions do not
continue and develop into partial or complete remissions is
not clear, but the outcome of several months ofimmunother-
apy is reasonably the end-result of a multistep process, e.g.
initial immune-mediated lysis of tumour cells, selection of
non-immunogenic tumour cell clones, down-regulation of the
immune response to the tumour. Thus, in order not to
misjudge the possibility of the immune system of these
patients responding to immunotherapy, significant minor and
mixed responses have to be included in the analyses.
Our study showed a close correlation between the
occurrence of CD4+ lymphocytes and the therapeutic benefit
of IFN-a. In patients with systemic disease, ten out of 11 of
those with moderate or high infiltration of CD4+ lympho-
cytes in the tumours achieved tumour regression. In contrast,
among patients with low infiltration ofthese cells, nine out of
ten had progressive disease. Based on these results there
seems to be a need for CD4+ lymphocytes infiltrating the
tumours before start of treatment with IFN-a to make the
treatment successful. Thus, the degree of infiltration of these
cells seems to be a useful predictive test for choosing patients
suitable for this therapy.
Different studies have been undertaken where adjuvant
IFN-a treatment was given to high-risk patients showing a
significant rise in relapse-free intervals (Kirkwood et al.,
1996). Perhaps also in this setting, patients most likely to
benefit from IFN--a treatment can be selected based on the
occurrence ofCD4+ cells, thus increasing the cost-benefit of
this treatment strategy considerably, in terms of both patient
adverse reactions and health care costs.
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